Fulcrum Therapeutics downgraded by H.C. Wainwright with a new price target
$FULC
Biotechnology: Pharmaceutical Preparations
Health Care
H.C. Wainwright downgraded Fulcrum Therapeutics from Buy to Neutral and set a new price target of $4.00 from $17.00 previously